Largest study to date of high-dose methotrexate associated acute kidney injury supports the use of Voraxaze® (glucarpidase)
11 déc. 2023 09h51 HE
|
BTG Specialty Pharmaceuticals
West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX)...
Vitrolife Signs Research Agreement With Dr. Peter Svalander
20 oct. 2004 08h58 HE
|
Vitrolife
STOCKHOLM, Sweden, Oct. 20, 2004 (PRIMEZONE) -- Vitrolife has signed a research agreement with Dr. Peter Svalander, the founder and former CEO of the company, regarding product development within the...
Pharmexa Reports Progress in U.S. Breast Cancer Trial
10 sept. 2003 09h43 HE
|
Pharmexa A/S
HORSHOLM, Denmark, Sept. 10, 2003 (PRIMEZONE) -- Summary: Recruitment of patients to the US phase I breast cancer trial with Pharmexa's (Other OTC:PMXAY) HER-2 AutoVac(TM) Protein vaccine has now...
Abbott Laboratories and Karo Bio Identify Novel new Compound for Diabetes
27 mars 2003 03h06 HE
|
Karo Bio
HUDDINGE, Sweden, March 27, 2003 (PRIMEZONE) -- Abbott Laboratories and Karo Bio AB (Other OTC:KARBF) today announced that they have identified a novel, first-in-class compound, A-348441, for the...
Cellzome Hits Target on Series C Financing
18 mars 2003 11h18 HE
|
Index Ventures
Heidelberg, Germany, March 18, 2003 - Cellzome today announced the completion of its Series C funding at a total of approximately 30 Million Pounds. Lead investor, INVESCO Private Capital, was...
CeNeS Pharmaceuticals plc: Interim Results Notification
13 sept. 2002 09h25 HE
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, United Kingdom, Sept. 13, 2002 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) will be announcing its interim results for the six months ended 30 June 2002 on Monday 30th September...
Carlsberg A/S: Combio Negotiating with Potential Customers
29 août 2002 07h07 HE
|
Carlsberg A/S
VALBY, Denmark, Aug. 29, 2002 (PRIMEZONE) -- In less than two years, the biotech company Combio A/S has managed to build up the company to start research and development of new, potential drug...